Tinnitus - Pipeline Review, H1 2017

Published: Apr, 2017 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus - Pipeline Review, H1 2017, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinnitus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tinnitus - Overview
Tinnitus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tinnitus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tinnitus - Companies Involved in Therapeutics Development
AudioCure Pharma GmbH
Auris Medical Holding AG
Knopp Biosciences LLC
Merz Pharma GmbH & Co KgaA
Otonomy Inc
SciFluor Life Sciences LLC
Sound Pharmaceuticals Inc
Tinnitus - Drug Profiles
AM-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-Methionine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esketamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gacyclidine SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
neramexane mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RL-81 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0034 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate KCNQ for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Kv7.2 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Neurotrophic Factor for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPI-1005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetrandrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tinnitus - Dormant Projects
Tinnitus - Product Development Milestones
Featured News & Press Releases
Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
Jan 26, 2017: Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus
Dec 06, 2016: Auris Medical on Track to Resume Enrollment of Keyzilen Tinnitus Program Following Regulatory Feedback
Oct 11, 2016: Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus
Oct 10, 2016: Auris Medical to Announce Keyzilen Program Update
Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus
Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million
Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus
Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus
Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus
Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City
Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus
Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311
Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Tinnitus, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Tinnitus - Pipeline by AudioCure Pharma GmbH, H1 2017
Tinnitus - Pipeline by Auris Medical Holding AG, H1 2017
Tinnitus - Pipeline by Knopp Biosciences LLC, H1 2017
Tinnitus - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2017
Tinnitus - Pipeline by Otonomy Inc, H1 2017
Tinnitus - Pipeline by SciFluor Life Sciences LLC, H1 2017
Tinnitus - Pipeline by Sound Pharmaceuticals Inc, H1 2017
Tinnitus - Dormant Projects, H1 2017